Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft

European Journal of Cancer

Volumn 34, Issue 6, 1998, Pages 908-913

  Keiner, M J ^a,c   McMorris, T C ^b   Estes, L ^a   Samson, K M ^b   Bagnell, R D ^a   Taetle, R ^b  

^a UCSD MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

6 hydroxymethylacylfulvene; Antitumour activity; Carcinoma; Gp170; HMAF; Mdr1; MGI 114; MV522; Non small cell lung cancer; NSC 683863; Xenograft

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; ANTINEOPLASTIC AGENT; DOXORUBICIN; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG; VINBLASTINE SULFATE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CHEMICAL STRUCTURE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EXPRESSION VECTOR; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIFESPAN; LUNG CARCINOMA; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MITOMYCIN; NEOPLASM TRANSPLANTATION; PACLITAXEL; SESQUITERPENES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032077401     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00033-1     Document Type: Article

References (31)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer Statistics 1997. CA Cancer J Clin 1997, 47, 5-27.
2. Lee JD, Ginsberg RJ. The multimodality treatment of stage III A/B non-small cell lung cancer. Hematol Oncol Clin 1997,11, 279-301.
3. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993, 342, 19-21.
4. Taylor CW, Crowley J, Williamson SK, et al. Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study. 3 Clin Oncol 1990, 8, 1811-1817.
5. Ries LAG, Hankey BF, Miller BA, Hartman AM, Edwards BK. Cancer statistics reviewed 1973-1988, National Cancer Institute, NIH Publication 91-2789, Bethesda, Maryland, 1991.
6. Ihde DC. Chemotherapy of lung cancer. New Engl J Med 1992, 27, 1434-1441.
7. Kelner MJ, McMorris TC, Beck W, Zamora JM, Taetle R. Preclinical evaluation of illudins as anticancer agents. Cancer Res 1987, 47, 3186-3189.
8. Kelner MJ, McMorris TC, Taetle R. Preclinical evaluation of illudins as anti-cancer agents. Basis for selective cytotoxicity. J Natl Cancer Inst 1990, 82, 156-165.
9. Kelner MJ, McMorris TC, Taetle R. In vitro and in vivo studies on the anticancer activity of dehydroilludin M. Anticancer Res 1995, 15, 873-878.
10. McMorris TC, Kelner MJ, Wang W, Estes LA, Montoya MM, Taetle R. Structure activity-relationships of illudins: analogs with improved therapeutic index. J Org Chem 1992,57, 176-183.
11. Kelner MJ, McMorris TC, Estes L, et al. Efficacy of acylfulvene illudin analogs against a metastatic lung carcinoma MV522 nonresponsive to traditional anticancer agents. Cancer Res 1995, 55, 4936-4940.
12. Kelner MJ, McMorris TC, Estes L, Wang W, Samson KM, Taetle R. Efficacy of HMAF (MGI 114) in the MV522 metastatic lung carcinoma model nonresponsive to traditional anticancer agents. Invest New Drugs 1996, 141, 161-167.
13. MacDonald JR, Muscoplat CC, Dexter DL, et al. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res 1997, 57, 279-283.
14. Kelner MJ, McMorris TC, Estes L, et al. Characterization of illudin S sensitivity in DNA repair deficient Chinese hamster cells: unusually high sensitivity of ERCC2 and ERCC3 DNA helicase deficient mutants in comparison to other chemotherapeutic agents. Biochem Pharmacol 1994, 48, 403-409.
15. Gottesman MM, Pastan I. The multidrug transporter, a double-edged sword. J Biol Chem 1988, 263, 12163-12166.
16. Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumours. Proc Natl Acad Sci USA 1994, 91, 3497-3504.
17. Dalton W, Sikic BI. The multidrug-resistance gene (MDR1) represents a potential target for reversing drug resistance in human malignancies. J NIH Res 1994, 6, 54-58.
18. Houghton PJ, Kaye SB. Multidrug resistance is not an important factor in therapeutic outcome in human malignancies. J NIH Res 1994, 6, 55-61.
19. Mross K. Multidrug-resistance modulation in metastatic breast cancer patients. J Clin Oncol 1995, 13, 303-304.
20. Preisler HD. Multidrug resistance is more than MDR1 activity. Leukemia Res 1995, 19, 429-431.
21. Ramachandran C, Sauertegit A, Sridhar KS, Thuler RJ, Krishan A. MDR-1 gene expression, anthracycline retention, and cytotoxicity in human-tumor cells from refractory patients. Cancer Chemother Pharmacol 1993, 31, 431-441.
22. Kelner MJ, McMorris TC, Estes L, et al. Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents. Anticancer Res 1995, 15, 867-872.
23. Monks A, Scuderio D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using adiverse panel of cultured human cell lines. J Natl Cancer Institute 1991, 83, 757-766.
24. McMorris TC, Anchel M. Fungal metabolites. The structures of the novel sesquiterpenes illudin-S and -M. J Am Chem Soc 1965, 87, 1594-1600.
25. McMorris TC, Kelner MJ, Wang W, Yu J, Estes L, Taetle R. Hydroxymethylacylfulvene: an illudin derivative with superior antitumor properties. J Natural Products 1996, 59, 896-899.
26. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC. A retrovirus carrying an mdr1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 1988, 85, 4486-4490.
27. Taetle R, Rosen F, Abramson I, Beneditti J, Howell S. Use of nude mouse xenografts as preclinical drug screen: in vivo activity of established chemotherapeutic agents against melanomas and ovarian carcinoma xenografts. Cancer Treat Rep 1987, 71, 297-304.
28. Taetle R, Dos Santos B, Akamatsu K-I, Koishihara Y, Ohsug Y. Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells. Clin Cancer Res 1996, 2, 253-259.
29. Altman DG. Practical Statistics in Medical Research. New York, NY, U.S.A. Chapman & Hall, 1991, 355-394.
30. Licht T, Aksentijevich I, Gottesman MM, Pastan I. Efficient expression of functional human MDR1 gene in murine bone marrow after retroviral transduction of purified hematopoietic stem cells. Blood 1995, 86, 111-121.
31. Metz MZ, Matsumoto L, Wintera KA, Doroshow JH, Kane SE. Bicistronic and two-gene retroviralectors for using MDR1 as a selectable marker and a therapeutic gene. Virology 1996, 217, 230-241.